Výsledky vyhledávání - "Hollis Viray, MD"

Akademický článek

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors

Autor: Ikei S. Kobayashi, MD, PhD, William Shaffer, MS, Hollis Viray, MD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 1, Pp 100614- (2024)

Introduction: Mechanisms of resistance to EGFR exon 20 insertion mutation active inhibitors have not been extensively studied in either robust preclinical models or patient-derived rebiopsy specimens. We sought to characterize on-target resistance mu

Externí odkaz: https://doaj.org/article/9d6f86ae7ca94cdea9028f4d32112c40

Zobrazit plný text záznamu

Akademický článek

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

Autor: Pedro E.N.S. Vasconcelos, MS, Carol Gergis, MS, Hollis Viray, MD, Andreas Varkaris, MD, PhD, Masanori Fujii, MD, PhD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

Publikováno v: JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100051- (2020)

Introduction: The EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation (∼5% to 6% of exon 20 insertions), which, at the structural and enzyme kinetic level, more closely resembles EGFR tyrosine kinase inhibitor (TKI)–sensitizing mutants,

Externí odkaz: https://doaj.org/article/b0e73be55f654db78b7ddafa36ce97a9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání